Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIdox Group Regulatory News (IDOX)

  • There is currently no data for IDOX

Trading Statement

16 Nov 2022 07:00

RNS Number : 5282G
IDOX PLC
16 November 2022
Β 

16 November 2022

Idox plc

('Idox',Β theΒ 'Group'Β orΒ theΒ 'Company')

Year End Trading Update

A resilient performance

Β 

Idox plc (AIM: IDOX), a leading supplier of specialist information management software and solutions to the public and asset intensive sectors, today issues a trading update for its financial year ended 31 October 2022 ('FY22').

Β 

Β 

Group trading performance

Β 

We are pleased to report Idox has delivered a resilient performance for FY22 against a backdrop of economic uncertainty. We have continued to make progress towards a number of our medium-term strategic goals, putting the Group on a strong footing for the future.

Β 

Our focus on winning and retaining long-term recurring revenue contracts with high quality customers has resulted in record full year order intake in excess of c. Β£74m, up 19% on FY21, providing good visibility into FY23.

Β 

The Board expects to report (subject to audit) a c. 15% increase in full year adjusted EBITDA to c. Β£22.5m, in line with management's expectations. Revenue is expected to be up 6% to c. Β£66m, and recurring revenue is anticipated to be up c. 12% over the period to c. Β£40.5m. As a result, the Group expects to deliver an improved adjusted EBITDA margin of c. 34% (FY21: 31%).

Β 

The Group's net debt at year-end was Β£6.7m, a reduction since 31 October 2021 (Β£8.1m net debt). The Group continues to maintain significant balance sheet flexibility and strength, including a Β£35m revolving credit facility and a Β£10m accordion.

Β 

As reported in early October, Idox acquired Landhawk, a land mapping and GIS data business, for Β£1.5m, including an initial cash consideration of Β£1.1m. Landhawk further strengthens the Group's GIS capabilities following the acquisitions of Aligned Assets, thinkWhere and exeGesIS in FY21. We continue to pursue a number of acquisition opportunities but remain focussed on ensuring strategic alignment whilst maintaining a disciplined approach to valuations.

Β 

We have started FY23 with strong recurring revenue and good levels of contract renewals, a solid order book and a healthy pipeline. As a result, our expectations for FY23 remain unchanged, albeit we remain cognisant of the current economic environment.

Β 

Β 

David Meaden, Chief Executive Officer of Idox commented:

Β 

"We have laid the foundations for sustained success at Idox, and against a challenging macro-economic backdrop, we have delivered a robust set of results.

With recurring revenue and order intake up, we are well positioned to continue our success over the coming years, supported by a strong balance sheet.

Β 

Pleasingly, we have seen significant success in areas of strategic focus, notably with Idox Cloud where we have seen 15 new sales during the period, which bodes well for our future performance.

Β The integration of recent acquisitions into the Group has progressed well and we have made several adjustments to our operating business, building capacity for future growth. I am pleased that our leadership development programme has ensured that all new senior appointees have been internal candidates.

Β 

We have a strong balance sheet position, leaving us well placed for an accretive buy and build programme. This, alongside our accelerating organic growth, will create significant value for shareholders and wider stakeholders going forward."

Β 

Β 

Β 

Β 

Β 

Β 

Notice of results

Β 

The Group expects to report its FY22 results in late January 2023. Management intends to host a results webinar on the day. Please contact MHP Communications to register your interest.

Β 

Β 

Definitions

Β 

Adjusted EBITDA is defined as earnings before amortisation, depreciation, restructuring, acquisition costs, impairment, financing costs and share option costs.

Β 

Net debt is defined as the aggregation of cash, bank borrowings and long-term bond.

Β 

Β 

For further information please contact:

Β 

Idox plc

Chris Stone, Non-Executive Chairman

David Meaden, Chief Executive Officer

Anoop Kang, Chief Financial Officer

Β 

+44 (0) 870 333 7101

investorrelations@idoxgroup.com

Peel Hunt LLP (NOMAD and Broker)

Paul Gillam

Michael Burke

James Smith

Β 

+44 (0) 20 7418 8900

MHP Communications

Reg Hoare

Ollie Hoare

Matthew Taylor

Β 

+ 44 (0) 20 3128 8276

idox@mhpc.com

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTFELLFLFLLFBK
Date   Source Headline
19th Feb 20217:39 amRNSStatement re Possible Offer
19th Feb 20217:00 amRNSStatement re Possible Offer
3rd Feb 20217:00 amRNSAGM Date & Dividend Payment Schedule
2nd Feb 20217:00 amRNSFY20 Results
19th Jan 20214:05 pmRNSExercise of Share Options & Total Voting Rights
19th Jan 20217:00 amRNSNotice of Final Results
2nd Dec 20207:00 amRNSContract Win
2nd Dec 20207:00 amRNSExercise of Share Options and Total Voting Rights
26th Nov 202011:37 amRNSInvestor presentation
17th Nov 20207:00 amRNSYear End Trading Update
27th Oct 20207:00 amRNSExercise of Share Options & Total Voting Rights
22nd Oct 20205:35 pmRNSHolding(s) in Company
21st Oct 20207:00 amRNSAppointment of Head of Professional Services
14th Oct 20205:45 pmRNSReplacement: Exercise of Share Options & TVR
14th Oct 202011:51 amRNSHolding(s) in Company
14th Oct 20207:00 amRNSIdox Rebrand and Recent Progress with Idox Cloud
13th Oct 20207:00 amRNSExercise of Share Options & Total Voting Rights
23rd Sep 20205:30 pmRNSHolding(s) in Company
28th Aug 20207:00 amRNSDirectorate Changes
25th Aug 20207:00 amRNSExercise of Share Options & Total Voting Rights
16th Jul 20207:00 amRNSExercise of Share Options & Total Voting Rights
8th Jul 20201:58 pmRNSHolding(s) in Company
19th Jun 20207:00 amRNSGrant of Options
15th Jun 20207:00 amRNSHalf-year Report
28th May 202011:18 amRNSResult of AGM
19th May 20207:00 amRNSHalf Year Trading Update
1st May 20207:42 amRNSPosting of Annual Report and Notice of AGM
28th Apr 20204:33 pmRNSHolding(s) in Company
20th Apr 20208:01 amRNSProgressive publishes new research
14th Apr 20207:01 amRNSDirectorate Change
14th Apr 20207:00 amRNSFinal Results
30th Mar 20204:36 pmRNSPrice Monitoring Extension
23rd Mar 20207:00 amRNSNotice of Results Update
16th Mar 20207:00 amRNSTrading Update and Notice of Results update
7th Feb 202011:33 amRNSHolding(s) in Company
7th Feb 202011:29 amRNSNotice of Results
23rd Jan 20207:00 amRNSChange of Adviser and Notice of Results
22nd Jan 202012:44 pmRNSAIM Rule 17 Schedule Two (g) Update
17th Jan 202012:12 pmRNSDirectors' Dealings & Holdings in Company
3rd Jan 20207:00 amRNSDirectors' Dealings & Holdings in Company
24th Dec 201912:49 pmRNSDirectors' Dealings & Holdings in Company
19th Dec 20197:00 amRNSNew Banking Facilities
2nd Dec 20192:45 pmRNSDirectors' Dealings & Holdings in Company
27th Nov 20192:54 pmRNSDirectors' Dealings & Holdings in Company
27th Nov 20192:10 pmRNSHolding(s) in Company
27th Nov 20192:08 pmRNSHolding(s) in Company
25th Nov 20197:00 amRNSYear End Trading Update
3rd Oct 20192:09 pmRNSExercise of Share Options & Total Voting Rights
17th Sep 20193:03 pmRNSHolding(s) in Company
30th Aug 201910:02 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.